医药行业周报（6.3-6.6）：持续关注AI医疗和创新药

Investment Rating - The report maintains a positive outlook on the pharmaceutical industry, highlighting investment opportunities in AI healthcare and innovative drugs [1]. Core Insights - The pharmaceutical sector index increased by 1.13% this week, outperforming the CSI 300 index by 0.25 percentage points, ranking 17th in industry performance [14]. - Year-to-date, the pharmaceutical industry has risen by 7.81%, surpassing the CSI 300 index by 9.36 percentage points, ranking 5th [14]. - The current valuation level (PE-TTM) for the pharmaceutical industry is 28.24 times, with a premium of 86.84% relative to the entire A-share market [19]. - The best-performing sub-sector this week was vaccines, which rose by 2.9%, while the top three sub-sectors year-to-date are chemical preparations, raw materials, and other biological products, with increases of +21.3%, +20.4%, and +16.1% respectively [28]. Summary by Sections Investment Strategy - The report emphasizes the acceleration of AI healthcare development and investment opportunities, with over 830 hospitals in China completing the localization of DeepSeek-R1, marking a new phase in medical intelligence [15]. - Continuous attention is recommended for innovative drugs, especially following the ASCO 2025 conference, where over 70 research abstracts led by Chinese scholars were presented [16]. Market Performance - The pharmaceutical industry has shown strong performance, with a notable increase in the number of stocks with positive returns, totaling 330, while 150 stocks experienced declines this week [29]. - The report lists the top gainers and losers in the pharmaceutical sector, with 易明医药 (Yiming Pharmaceutical) leading with a gain of +33.1% and *ST龙津 (ST Longjin) facing a decline of -36.3% [29]. Recent News and Policies - The report highlights the ongoing trend of AI integration in healthcare, with significant advancements in clinical decision support systems and AI-assisted diagnostics [15]. - It also notes the importance of focusing on drug development that is patient-centered and clinically valuable, aligning with the broader themes of innovation and internationalization in the pharmaceutical industry [16].